Eloxx Q2 Loss Widens; Exaluren Phase 2b Trial Set To Begin In Q3 2026

Eloxx Pharmaceuticals (ELOX) reported a Q2 2026 net loss of $4.5M, while cash and equivalents reached $62M following a $66M public offering. The company expects to initiate a Phase 2b trial of exaluren in nonsense mutation Alport syndrome in Q3 2026.